CNS Pharmaceuticals (CNSP) Non Operating Income (2019 - 2025)
CNS Pharmaceuticals' (CNSP) quarterly Non Operating Income came in at $30324.0 in Q4 2025, up 28.05% YoY from $23682.0 in Q4 2024, and down 13.13% on a QoQ basis from $34907.0 in Q3 2025.
CNS Pharmaceuticals (CNSP) Non Operating Income (2019 - 2025) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 7 years of Non Operating Income data on file, last reported at $30324.0 in Q4 2025.
- Quarterly Non Operating Income rose 28.05% year-over-year to $30324.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $135995.0 (up 208.09% YoY) and the FY2025 annual result came in at $135995.0, up 208.09% from the prior year.
- Non Operating Income retreated to $30324.0 in Q4 2025, from $34907.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $36340.0 in Q1 2025 to a low of -$5436.0 in Q1 2023.
- A 5-year average of $8885.4 and a median of -$216.0 in 2022 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2024 — Non Operating Income plunged 163.05% — and 2025, when it surged 34183.02%.
- Tracing CNSP's Non Operating Income over 5 years: stood at -$2238.0 in 2021, then fell by 3.31% to -$2312.0 in 2022, then soared by 278.24% to $4121.0 in 2023, then soared by 474.67% to $23682.0 in 2024, then rose by 28.05% to $30324.0 in 2025.
- The last three Non Operating Income figures came in at $30324.0 (Q4 2025), $34907.0 (Q3 2025), and $34424.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | CNS Pharmaceuticals | 2.65 Mn | -4.55 Mn | - | 30,324.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 30,324.00 |
| Sep 30, 2025 | 34,907.00 |
| Jun 30, 2025 | 34,424.00 |
| Mar 31, 2025 | 36,340.00 |
| Dec 31, 2024 | 23,682.00 |
| Sep 30, 2024 | 22,972.00 |
| Jun 30, 2024 | -2,618.00 |
| Mar 31, 2024 | 106.00 |
| Dec 31, 2023 | 4,121.00 |
| Sep 30, 2023 | 11,045.00 |
| Jun 30, 2023 | 4,152.00 |
| Mar 31, 2023 | -5,436.00 |
| Dec 31, 2022 | -2,312.00 |
| Sep 30, 2022 | -538.00 |
| Jun 30, 2022 | -1,611.00 |
| Mar 31, 2022 | -2,566.00 |
| Dec 31, 2021 | -2,238.00 |
| Sep 30, 2021 | -947.00 |
| Jun 30, 2021 | -2,353.00 |
| Mar 31, 2021 | -3,747.00 |